<DOC>
	<DOC>NCT00354562</DOC>
	<brief_summary>To determine the efficacy of ABT-751 when administered in combination with standard docetaxel in subjects with advanced or metastatic NSCLC.</brief_summary>
	<brief_title>A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Pathologically documented NSCLC Locally advanced (Stage III) or metastatic (Stage IV) NSCLC Only one prior antitumor treatment regimen in the noncurative setting (i.e., 2ndline therapy) Only one prior antitumor treatment regimen in the curative setting Progressive disease following the previous antitumor treatment regimen Measurable disease by RECIST criteria Brain metastasis must be stable and wellcontrolled ECOG performance score 02All antitumor therapy discontinued at least 3 weeks prior to study entryAll adverse events from prior treatment are resolved or stableAdequate hematologic, renal, and hepatic functionFemales must not be pregnantWilling to take adequate measures to prevent pregnancyLife expectancy of at least 3 monthsAble to complete the Quality of Life questionnaireVoluntarily signed informed consent Only one prior antitumor treatment regimen in the curative setting Progressive disease following the previous antitumor treatment regimen Measurable disease by RECIST criteria Brain metastasis must be stable and wellcontrolled ECOG performance score 02 All antitumor therapy discontinued at least 3 weeks prior to study entry All adverse events from prior treatment are resolved or stable Adequate hematologic, renal, and hepatic function Females must not be pregnant Willing to take adequate measures to prevent pregnancy Life expectancy of at least 3 months Able to complete the Quality of Life questionnaire Voluntarily signed informed consent Greater that Grade 1 neurological findings Allergy to sulfa medications Previous treatment with ABT751 or docetaxel Receipt of more than one investigational agent for NSCLC Significant weight loss (&gt;10%) within 6 weeks of study entry Glucose6phosphate dehydrogenase deficiency or porphyria Significant systemic disease that would adversely affect participation Class 34 New York Heart Association classification status Other cancers except in situ carcinoma of the cervix, basal or squamous cell skin cancer, or any other cancer considered adequately treated and cured by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>ABT-751</keyword>
	<keyword>docetaxel</keyword>
	<keyword>Taxotere</keyword>
</DOC>